248 related articles for article (PubMed ID: 27044938)
1. Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.
Hong D; Infante J; Janku F; Jones S; Nguyen LM; Burris H; Naing A; Bauer TM; Piha-Paul S; Johnson FM; Kurzrock R; Golden L; Hynes S; Lin J; Lin AB; Bendell J
J Clin Oncol; 2016 May; 34(15):1764-71. PubMed ID: 27044938
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Bendell JC; Bischoff HG; Hwang J; Reinhardt HC; Zander T; Wang X; Hynes S; Pitou C; Campbell R; Iversen P; Farrington DL; Bell-McGuinn K; Thomas M
Invest New Drugs; 2020 Aug; 38(4):1145-1155. PubMed ID: 31707688
[TBL] [Abstract][Full Text] [Related]
3. Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors.
Iwasa S; Yamamoto N; Shitara K; Tamura K; Matsubara N; Tajimi M; Lin AB; Asou H; Cai Z; Inoue K; Shibasaki Y; Saito K; Takai H; Doi T
Cancer Sci; 2018 Oct; 109(10):3216-3223. PubMed ID: 30040168
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).
Cash T; Fox E; Liu X; Minard CG; Reid JM; Scheck AC; Weigel BJ; Wetmore C
Pediatr Blood Cancer; 2021 Sep; 68(9):e29065. PubMed ID: 33881209
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
Hong DS; Moore K; Patel M; Grant SC; Burris HA; William WN; Jones S; Meric-Bernstam F; Infante J; Golden L; Zhang W; Martinez R; Wijayawardana S; Beckmann R; Lin AB; Eng C; Bendell J
Clin Cancer Res; 2018 Jul; 24(14):3263-3272. PubMed ID: 29643063
[No Abstract] [Full Text] [Related]
6. Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
Macaulay VM; Middleton MR; Eckhardt SG; Rudin CM; Juergens RA; Gedrich R; Gogov S; McCarthy S; Poondru S; Stephens AW; Gadgeel SM
Clin Cancer Res; 2016 Jun; 22(12):2897-907. PubMed ID: 26831715
[TBL] [Abstract][Full Text] [Related]
7. A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors.
Mita M; Gordon M; Rejeb N; Gianella-Borradori A; Jego V; Mita A; Sarantopoulos J; Sankhala K; Mendelson D
Target Oncol; 2014 Sep; 9(3):215-24. PubMed ID: 23832397
[TBL] [Abstract][Full Text] [Related]
8. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
Daud AI; Ashworth MT; Strosberg J; Goldman JW; Mendelson D; Springett G; Venook AP; Loechner S; Rosen LS; Shanahan F; Parry D; Shumway S; Grabowsky JA; Freshwater T; Sorge C; Kang SP; Isaacs R; Munster PN
J Clin Oncol; 2015 Mar; 33(9):1060-6. PubMed ID: 25605849
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.
Byers LA; Navarro A; Schaefer E; Johnson M; Özgüroğlu M; Han JY; Bondarenko I; Cicin I; Dragnev KH; Abel A; Wang X; McNeely S; Hynes S; Lin AB; Forster M
Clin Lung Cancer; 2021 Nov; 22(6):531-540. PubMed ID: 34034991
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
11. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
[TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.
Nishina T; Takahashi S; Iwasawa R; Noguchi H; Aoki M; Doi T
Invest New Drugs; 2018 Jun; 36(3):424-434. PubMed ID: 28965185
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
14. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
15. A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Aghajanian C; Bell-McGuinn KM; Burris HA; Siu LL; Stayner LA; Wheler JJ; Hong DS; Kurkjian C; Pant S; Santiago-Walker A; Gauvin JL; Antal JM; Opalinska JB; Morris SR; Infante JR
Invest New Drugs; 2018 Dec; 36(6):1016-1025. PubMed ID: 29611022
[TBL] [Abstract][Full Text] [Related]
16. Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development.
Angius G; Tomao S; Stati V; Vici P; Bianco V; Tomao F
Cancer Chemother Pharmacol; 2020 Jan; 85(1):9-20. PubMed ID: 31512029
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.
Jones RL; Kim ES; Nava-Parada P; Alam S; Johnson FM; Stephens AW; Simantov R; Poondru S; Gedrich R; Lippman SM; Kaye SB; Carden CP
Clin Cancer Res; 2015 Feb; 21(4):693-700. PubMed ID: 25208878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
